Adibendan

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 591152

CAS#: 100510-33-6

Description: Adibendan is an inhibitor of phosphodiesterase III.

Chemical Structure

img
Adibendan
CAS# 100510-33-6
Instruction

Theoretical Analysis

MedKoo Cat#: 591152
Name: Adibendan
CAS#: 100510-33-6
Chemical Formula: C16H14N4O
Exact Mass: 278.12
Molecular Weight: 278.320
Elemental Analysis: C, 69.05; H, 5.07; N, 20.13; O, 5.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Adibendan;

IUPAC/Chemical Name: Pyrrolo(2,3-f)benzimidazol-6(1H)-one, 5,7-dihydro-7,7-dimethyl-2-(4-pyridinyl)-

InChi Key: TVLQBBHUNDMTEC-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14N4O/c1-16(2)10-7-12-13(8-11(10)20-15(16)21)19-14(18-12)9-3-5-17-6-4-9/h3-8H,1-2H3,(H,18,19)(H,20,21)

SMILES Code: O=C(N1)C(C)(C)C2=C1C=C3N=C(C4=CC=NC=C4)NC3=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 278.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schneider J, Beck E, Heers C, Conrad C, de Chaffoy de Courcelles D, Wilffert B, Peters T. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):563-72. PubMed PMID: 1470228.

2: de Cheffoy de Courcelles D, de Loore K, Freyne E, Janssen PA. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. PubMed PMID: 1328613.

3: Murray KJ, England PJ. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents. Biochem Soc Trans. 1992 May;20(2):460-4. Review. PubMed PMID: 1327922.

4: Ling Y. [Research on a new type of cardiotonic agents with calcium-sensitizing activity]. Sheng Li Ke Xue Jin Zhan. 1992 Jan;23(1):41-5. Review. Chinese. PubMed PMID: 1329193.

5: Schmitz W, Eschenhagen T, Mende U, Müller FU, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Basic Res Cardiol. 1992;87 Suppl 1:65-71. PubMed PMID: 1323266.

6: Wilhelm D, Wilffert B, Janssens WJ, Leidig A, Meuter C, Ebbert M, Peters T. In vitro pharmacology of R 80122, a novel phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1992;20(5):705-14. PubMed PMID: 1280731.

7: von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. PubMed PMID: 1723153.

8: Rauch B, Zimmermann R, Kapp M, Haass M, Von Molitor S, Smolarz A, Neumann FJ, Kübler W, Dietz R, Tillmanns H. Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure. Clin Cardiol. 1991 May;14(5):386-95. PubMed PMID: 2049889.

9: Dorszewski A, Müller-Beckmann B, Kling L, Sponer G. Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs. Br J Pharmacol. 1990 Nov;101(3):686-90. PubMed PMID: 2076485; PubMed Central PMCID: PMC1917742.

10: Peters P, Saborowski F, May E, Schneider M. [Central hemodynamics of a new positive inotropic substance, adibendan. Data from a dose-finding study]. Arzneimittelforschung. 1990 Jun;40(6):666-8. German. PubMed PMID: 2397002.

11: Kitada Y, Morita M, Narimatsu A. Comparison of the effects of MCI-154, a new cardiotonic agent, and some Ca2+-sensitizing agents on the response of the contractile system to Ca2+ in skinned cardiac muscle. Jpn J Pharmacol. 1989 Aug;50(4):411-9. PubMed PMID: 2789299.

12: Voelker W, Mauser M, Preisack M, Karsch KR. Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for severe congestive heart failure. Am J Cardiol. 1989 Aug 1;64(5):390-2. PubMed PMID: 2756885.

13: von der Saal W, Hölck JP, Kampe W, Mertens A, Müller-Beckmann B. Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles. J Med Chem. 1989 Jul;32(7):1481-91. PubMed PMID: 2544724.

14: Neubert P, Hölck JP. Automated pre-column high-performance liquid chromatographic method for the investigation of adibendan metabolism. J Chromatogr. 1989 May 5;490(1):155-64. PubMed PMID: 2760147.

15: Rüegg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol. 1989;14 Suppl 3:S20-3. PubMed PMID: 2478799.

16: Bethke T, Brunkhorst D, von der Leyen H, Meyer W, Nigbur R, Scholz H. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):576-82. PubMed PMID: 2457816.

17: Müller-Beckmann B, Freund P, Honerjäger P, Kling L, Rüegg JC. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol. 1988 Jan;11(1):8-16. PubMed PMID: 2450261.

18: Müller-Beckmann B, Sponer G, Strein K, Bartsch W. Hemodynamic profile of BM 14.478: a new positive inotropic and vasodilating agent. J Cardiovasc Pharmacol. 1988 Jan;11(1):1-7. PubMed PMID: 2450246.

19: Reiff K. High-performance liquid chromatographic method for the determination of adibendan in plasma and urine. J Chromatogr. 1987 Nov 27;422:346-52. PubMed PMID: 3437024.

20: Freund P, Müller-Beckmann B, Strein K, Kling L, Rüegg JC. Ca2+-sensitizing effect of BM 14.478 on skinned cardiac muscle fibres of guinea-pig papillary muscle. Eur J Pharmacol. 1987 Apr 14;136(2):243-6. PubMed PMID: 3595723.